Health status of prevalent cancer cases as measured by mortality dynamics (cancer vs. noncancer): Application to five major cancers sites

Cancer prevalence is heterogeneous because it includes individuals who are undergoing initial treatment and those who are in remission, experiencing relapse, or cured. The proposed statistical approach describes the health status of this group by estimating the probabilities of death among prevalent cases. The application concerns colorectal, lung, breast, and prostate cancers and melanoma in France in 2017.

[1]  G. Defossez,et al.  Cancer incidence and mortality trends in France over 1990–2018 for solid tumors: the sex gap is narrowing , 2021, BMC Cancer.

[2]  P. Dickman,et al.  Cancer survival statistics for patients and healthcare professionals – a tutorial of real‐world data analysis , 2020, Journal of internal medicine.

[3]  M. Bøgsted,et al.  On estimating the time to statistical cure , 2020, BMC Medical Research Methodology.

[4]  Ahmedin Jemal,et al.  Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[5]  D. Serraino,et al.  Major patterns of cancer cure: Clinical implications. , 2019, European journal of cancer care.

[6]  V. Jooste,et al.  Time-to-cure and cure proportion in solid cancers in France. A population based study. , 2019, Cancer epidemiology.

[7]  V. Jooste,et al.  Time trends and short term projections of cancer prevalence in France. , 2018, Cancer epidemiology.

[8]  J. Barnholtz-Sloan,et al.  A comparison of relative survival and cause‐specific survival methods to measure net survival in cancer populations , 2018, Cancer medicine.

[9]  V. Jooste,et al.  A new approach to estimate time-to-cure from cancer registries data. , 2018, Cancer epidemiology.

[10]  N. Voirin,et al.  Survival of solid cancer patients in France, 1989–2013: a population-based study , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[11]  B. Rachet,et al.  Analysing population-based cancer survival – settling the controversies , 2016, BMC Cancer.

[12]  P. Grosclaude,et al.  [Prostate cancer incidence and mortality trends in France from 1980 to 2011]. , 2015, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[13]  M. Federico,et al.  Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Ferlay,et al.  Global estimates of cancer prevalence for 27 sites in the adult population in 2008 , 2013, International journal of cancer.

[15]  Paul C. Lambert,et al.  Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model , 2011 .

[16]  P C Lambert,et al.  Estimating the crude probability of death due to cancer and other causes using relative survival models , 2010, Statistics in medicine.

[17]  Jacques Ferlay,et al.  NORDCAN – a Nordic tool for cancer information, planning, quality control and research , 2010, Acta oncologica.

[18]  Paul C. Lambert,et al.  Further Development of Flexible Parametric Models for Survival Analysis , 2009 .

[19]  Paul C Lambert,et al.  Flexible parametric models for relative survival, with application in coronary heart disease , 2007, Statistics in medicine.

[20]  P. Royston,et al.  Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.